← The Wire
OCULNasdaq
OCULAR THERAPEUTIX, INC
Pharmaceutical Preparations · DE · CIK 1393434
Develops and commercializes ophthalmic therapies using proprietary hydrogel technology for sustained drug delivery
red 8-K · 90d
$1.96B
Market cap
$9.90
Last close
+0.6%
1D
-0.7%
5D
2.1M
Volume
Price · last 39 sessions+1.3%
May 4L $7.99 · H $10.12Jun 29
273
Total filings
Jun 12, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteJun 12, 202610-Q10-QMay 5, 20268-KResults of OperationsMay 5, 2026DEFA14ADEFA14AApr 30, 2026DEF 14ADEF 14AApr 30, 20268-KReg FD DisclosureFeb 27, 202610-K10-KFeb 5, 20268-KResults of OperationsFeb 5, 20268-KExecutive ChangeJan 23, 20268-KCompany UpdateDec 18, 20258-KCompany UpdateDec 5, 202510-Q10-QNov 4, 20258-KResults of OperationsNov 4, 2025424B5424B5Sep 30, 20258-KMaterial Agreement · Company UpdateSep 30, 20258-KCompany UpdateSep 30, 202510-Q10-QAug 5, 20258-KResults of OperationsAug 5, 20258-KExecutive Change · Bylaw AmendmentJun 11, 202510-Q10-QMay 5, 20258-KResults of OperationsMay 5, 2025DEFA14ADEFA14AApr 29, 2025DEF 14ADEF 14AApr 29, 202510-K10-KMar 3, 20258-KResults of OperationsMar 3, 20258-KExecutive ChangeFeb 14, 2025SC 13GOCULAR THERAPEUTIX, INC.Nov 14, 202410-Q10-QNov 14, 20248-KResults of OperationsNov 14, 20248-KExecutive ChangeOct 9, 20248-KExecutive ChangeSep 3, 202410-Q10-QAug 7, 20248-KResults of OperationsAug 7, 20248-KExecutive Change · Bylaw AmendmentJun 14, 20248-KExit / Disposal CostsJun 3, 202410-Q10-QMay 7, 20248-KResults of OperationsMay 7, 2024DEFA14ADEFA14AMay 7, 2024DEF 14ADEF 14AApr 29, 20248-KExecutive ChangeApr 18, 20248-KCompany UpdateMar 29, 202410-K10-KMar 11, 20248-KResults of OperationsMar 11, 20248-KExecutive Change · Material AgreementFeb 22, 20248-KCompany UpdateJan 25, 2024SC 13GSC 13GDec 28, 2023SC 13GSC 13GDec 22, 2023424B5424B5Dec 14, 20238-KMaterial Agreement · Company UpdateDec 14, 2023424B5424B5Dec 13, 202310-Q10-QNov 7, 20238-KResults of OperationsNov 7, 20238-KReg FD DisclosureOct 4, 20238-KCompany UpdateOct 3, 20238-KCompany UpdateSep 13, 202310-Q10-QAug 7, 20238-KResults of OperationsAug 7, 20238-KExecutive ChangeJul 12, 20238-KMaterial AgreementJul 7, 20238-KExecutive Change · Shareholder VoteJun 16, 20238-KCompany UpdateJun 12, 202310-Q10-QMay 8, 20238-KResults of OperationsMay 8, 2023DEFA14ADEFA14AMay 1, 2023DEF 14ADEF 14AMay 1, 20238-KMaterial AgreementApr 6, 202310-K10-KMar 6, 20238-KResults of OperationsMar 6, 20238-KResults of OperationsJan 6, 202310-Q10-QNov 7, 20228-KResults of OperationsNov 7, 20228-KReg FD DisclosureSep 30, 202210-Q10-QAug 8, 20228-KResults of OperationsAug 8, 20228-KExecutive Change · Shareholder VoteJun 17, 20228-KExecutive ChangeJun 8, 202210-Q10-QMay 9, 20228-KResults of OperationsMay 9, 2022DEFA14ADEFA14AMay 2, 2022DEF 14ADEF 14AMay 2, 2022
Insider Activity
In the 90 days to Feb 23, 2026: 1 insider bought $461K · 6 sold $1.8M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 23, 2026 | Dugel PravinSee Remarks | Sell | 20,056 | $8.28 | $166K |
| Feb 23, 2026 | Heier Jeffrey S.Chief Scientific Officer | Sell | 3,057 | $8.28 | $25K |
| Feb 23, 2026 | Kaiser PeterChief Development Officer | Sell | 2,810 | $8.28 | $23K |
| Feb 23, 2026 | Nayak SanjayChief Strategy Officer | Sell | 1,759 | $8.28 | $15K |
| Feb 20, 2026 | Lindstrom Richard L MdDirector | Buy | 60,229 | $7.66 | $461K |
| Feb 20, 2026 | Waheed NadiaChief Medical Officer | Sell | 3,510 | $7.74 | $27K |
| Feb 12, 2026 | Dugel PravinSee Remarks | Sell | 124,882 | $9.04 | $1.1M |
| Feb 12, 2026 | Notman DonaldChief Operating Officer | Sell | 11,446 | $9.04 | $103K |
| Feb 12, 2026 | Nayak SanjayChief Strategy Officer | Sell | 10,348 | $9.04 | $94K |
| Feb 12, 2026 | Waheed NadiaChief Medical Officer | Sell | 7,863 | $9.04 | $71K |
| Feb 4, 2026 | Notman DonaldChief Operating Officer | Sell | 6,035 | $8.54 | $52K |
| Feb 2, 2026 | Notman DonaldChief Operating Officer | Sell | 5,455 | $9.14 | $50K |
| Nov 24, 2025 | Dugel PravinSee Remarks | Sell | 19,530 | $12.04 | $235K |
| Nov 24, 2025 | Heier Jeffrey S.Chief Scientific Officer | Sell | 3,469 | $12.04 | $42K |
| Nov 24, 2025 | Kaiser PeterChief Development Officer | Sell | 3,007 | $12.02 | $36K |
| Nov 24, 2025 | Nayak SanjayChief Strategy Officer | Sell | 1,878 | $12.04 | $23K |
| Nov 5, 2025 | Saroj NamrataChief Business Officer | Sell | 25,865 | $10.74 | $278K |
| Oct 8, 2025 | Anderman ToddChief Legal Officer | Sell | 11,132 | $12.34 | $137K |
| Oct 2, 2025 | Heier Jeffrey S.Chief Scientific Officer | Sell | 10,502 | $11.04 | $116K |
| Oct 2, 2025 | Kaiser PeterChief Development Officer | Sell | 9,653 | $11.03 | $106K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance